Nektar Therapeutics (NASDAQ:NKTR) Insider Sells $10,403.00 in Stock

Nektar Therapeutics (NASDAQ:NKTR) insider Jonathan Zalevsky sold 10,300 shares of the firm’s stock in a transaction dated Wednesday, February 19th. The stock was sold at an average price of $1.01, for a total transaction of $10,403.00. Following the completion of the sale, the insider now directly owns 316,604 shares of the company’s stock, valued at approximately $319,770.04. The trade was a 3.15 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Jonathan Zalevsky also recently made the following trade(s):

• On Thursday, December 19th, Jonathan Zalevsky sold 51,115 shares of Nektar Therapeutics stock. The stock was sold at an average price of $0.94, for a total value of $48,048.10.

Nektar Therapeutics Stock Down 2.6 %

Shares of NASDAQ NKTR opened at $0.93 on Monday. The firm has a market cap of $171.95 million, a PE ratio of -1.11 and a beta of 0.58. Nektar Therapeutics has a twelve month low of $0.63 and a twelve month high of $1.93. The business has a fifty day simple moving average of $0.92 and a two-hundred day simple moving average of $1.12.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. SG Americas Securities LLC grew its stake in Nektar Therapeutics by 30.4% in the third quarter. SG Americas Securities LLC now owns 95,637 shares of the biopharmaceutical company’s stock valued at $124,000 after purchasing an additional 22,285 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. lifted its position in Nektar Therapeutics by 5.6% during the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 650,841 shares of the biopharmaceutical company’s stock valued at $846,000 after acquiring an additional 34,599 shares during the last quarter. Intech Investment Management LLC acquired a new stake in Nektar Therapeutics in the third quarter valued at approximately $41,000. Valence8 US LP purchased a new position in Nektar Therapeutics in the third quarter worth $34,000. Finally, The Manufacturers Life Insurance Company acquired a new position in Nektar Therapeutics during the 3rd quarter valued at about $86,000. 75.88% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several equities analysts have commented on the company. B. Riley started coverage on Nektar Therapeutics in a research report on Wednesday, January 8th. They issued a “buy” rating and a $4.00 price objective on the stock. Piper Sandler began coverage on shares of Nektar Therapeutics in a research note on Monday, November 4th. They set an “overweight” rating and a $7.00 target price for the company. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $6.50 price target on shares of Nektar Therapeutics in a research note on Monday, January 13th. Two investment analysts have rated the stock with a hold rating, four have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $4.08.

Nektar Therapeutics Company Profile

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 2b clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1 clinical trial to boost the immune system's natural ability to fight cancer.